Company Overview of Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation researches, develops, manufactures, and markets medicines and treatments for helping patients and improving patient care. It offers prescription drugs to treat various diseases and conditions, including cancer, cardiovascular, central nervous system, endocrine, inflammatory, ophthalmic, infectious, neurological, organ transplantation, psychiatric, respiratory, skin, and infectious diseases and conditions. The company also provides patient assistance programs to manage diseases and conditions. Novartis Pharmaceuticals Corporation was formerly known as Sandoz Pharmaceuticals Corporation and changed its name to Novartis Pharmaceuticals Corporation in March 1...
One Health Plaza
East Hanover, NJ 07936-1080
Founded in 1968
Key Executives for Novartis Pharmaceuticals Corporation
President, US Country Head and President of Novartis Corporation
Chief Financial & Administrative Officer and Vice President
Chief Compliance Officer, Vice President and Us Country Head of Ethics & Compliance
Vice President, General Counsel and US Country Head of Legal
Vice President of Communications and US Country Head of Communications
Compensation as of Fiscal Year 2017.
Novartis Pharmaceuticals Corporation Key Developments
Novartis Pharmaceuticals Corporation Announce Acceptance of US Food and Drug Administration to Review Biologics License Application (Bla) for AMG 334
Jul 20 17
Novartis announced that the US Food and Drug Administration has accepted for review the Biologics License Application (BLA) for AMG 334 (erenumab) for the prevention of migraine in patients experiencing four or more migraine days per month. If approved, erenumab is expected to be the first and only fully human monoclonal antibody targeting the calcitonin gene-related peptide receptor, specifically designed for the prevention of migraine. Phase II and Phase III clinical studies of erenumab versus placebo have demonstrated a significant reduction in the number of migraine-affected days, acute medication over-use and disability, while improving quality of life for patients with episodic and chronic migraine. The safety profile of erenumab was similar to placebo in over 2,600 patients in the Phase II and Phase III studies assessing the prevention of migraine, and persistence rates were approximately 90%. AMG 334 (erenumab) is the only fully human monoclonal antibody specifically designed for the prevention of migraine that has been filed with the FDA. Erenumab specifically inhibits the receptor of the calcitonin gene-related peptide (CGRP), which is thought to play a causal role in migraine pathophysiology. Erenumab has been studied in several large global, randomized, double-blind, placebo-controlled trials to assess its safety and efficacy in migraine prevention.
Novartis Pharmaceuticals Corporation Presents at CASSS’ CMC Strategy Forum Summer 2017, Jul-18-2017 12:00 PM
Jul 14 17
Novartis Pharmaceuticals Corporation Presents at CASSS’ CMC Strategy Forum Summer 2017, Jul-18-2017 12:00 PM. Venue: Gaithersburg, Maryland, United States. Speakers: Cynthia Riggins.
Novartis Pharmaceuticals Presents at St. Petersburg International Economic Forum 2017 Programme, Jun-03-2017 08:30 AM
May 30 17
Novartis Pharmaceuticals Presents at St. Petersburg International Economic Forum 2017 Programme, Jun-03-2017 08:30 AM. Venue: St. Petersburg, Russia. Speakers: Nikolaos Tripodis, Managing Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|